BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Rating of “Hold” by Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has received an average recommendation of “Hold” from the ten brokerages that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $9.75.

BCRX has been the topic of a number of research reports. Needham & Company LLC reissued a “hold” rating on shares of BioCryst Pharmaceuticals in a report on Wednesday, November 6th. BidaskClub downgraded shares of BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, October 4th. HC Wainwright reissued a “buy” rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a report on Thursday, October 31st. Zacks Investment Research downgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 8th. Finally, ValuEngine downgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, November 4th.

Shares of BCRX traded down $0.13 on Monday, reaching $1.90. The company’s stock had a trading volume of 24,111 shares, compared to its average volume of 1,473,949. The company has a debt-to-equity ratio of 2.38, a current ratio of 1.44 and a quick ratio of 1.43. The stock has a market capitalization of $224.19 million, a P/E ratio of -1.94 and a beta of 1.86. The stock’s 50 day simple moving average is $2.53 and its two-hundred day simple moving average is $3.71. BioCryst Pharmaceuticals has a 12-month low of $1.95 and a 12-month high of $9.95.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03). The business had revenue of $1.78 million during the quarter, compared to analysts’ expectations of $4.54 million. BioCryst Pharmaceuticals had a negative return on equity of 371.33% and a negative net margin of 1,091.44%. Analysts expect that BioCryst Pharmaceuticals will post -1.23 earnings per share for the current year.

A number of large investors have recently modified their holdings of BCRX. FMR LLC lifted its holdings in BioCryst Pharmaceuticals by 15.9% during the first quarter. FMR LLC now owns 3,467,998 shares of the biotechnology company’s stock valued at $28,229,000 after purchasing an additional 475,989 shares in the last quarter. Commonwealth Equity Services LLC lifted its holdings in BioCryst Pharmaceuticals by 22.8% during the second quarter. Commonwealth Equity Services LLC now owns 53,230 shares of the biotechnology company’s stock valued at $201,000 after purchasing an additional 9,900 shares in the last quarter. First Midwest Bank Trust Division purchased a new position in BioCryst Pharmaceuticals during the second quarter valued at approximately $1,791,000. Quantitative Systematic Strategies LLC lifted its holdings in BioCryst Pharmaceuticals by 297.3% during the second quarter. Quantitative Systematic Strategies LLC now owns 43,590 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 32,618 shares in the last quarter. Finally, First Trust Advisors LP bought a new stake in shares of BioCryst Pharmaceuticals during the second quarter valued at approximately $188,000. 90.67% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Further Reading: What is Considered a Good Return on Equity (ROE)?

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.